#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypersomnia Gastrointestinal neuroendocrine tumour Arrhythmogenic right ventricular dysplasia Idiopathic intracranial hypertension Hypereosinophilic syndrome Extra-osseous Ewing's sarcoma metastatic Acute myeloid leukaemia recurrent Short stature homeobox gene mutation Loss of consciousness Hypochromic anaemia Cholangitis sclerosing Polymyositis Transferrin decreased Biliary cancer metastatic Primary amyloidosis More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Diagnostics Optic glioma – Life with Disease Glomerulonephritis membranoproliferative Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Glycogen storage disease type I – Life with Disease Osteosarcoma metastatic – Basic Information Toxic epidermal necrolysis – Treatment Inclusion body myositis – Trials in Disease Medulloblastoma recurrent – Diagnostics Gaucher’s disease type III – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tramadol Hydrochloride AZD1163 Pemetrexed Disodium PRILOCAINE HYDROCHLORIDE Ribonucleic Acid K10 Acetic Acid, Glacial Codeine Phosphate Hemihydrate Regorafenib Wve-006 Streptococcus Agalactiae Sodium Chloride Vepdegestrant Fenoterol Hydrobromide Pentixather Capecitabine Alanine Cyclophosphamide Formoterol Fumarate Dihydrate Zilucoplan Sodium Mva-209-Fsp-B4 More therapies…

    Learn about Your Condition

    Pulmonary venous thrombosis Netherton's syndrome Hypothyroidism Diabetic neuropathy Non-Hodgkin's lymphoma Portal hypertension Antithrombin III deficiency Fungal infection Device related infection Breast cancer stage II Chorea Laparotomy Adenovirus infection Myeloid leukaemia Intermittent claudication More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Clinique Pasteur

Clinique Pasteur

45 Avenue De Lombez, Cs 27617, Toulouse, 31076, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Apalutamide
    • Docetaxel
    France Germany Italy Portugal Spain

  • One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    France

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Hydroxocobalamin
    • Sotorasib
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • AZD5335
    • Doxorubicin Hydrochloride, Liposomal
    Belgium Czechia Denmark France Germany Greece +4

  • Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab Deruxtecan
    France Germany Spain

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Cyclophosphamide
    • Docetaxel
    Belgium France Greece Ireland Italy Poland +1

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Carboplatin
    • Cyclophosphamide
    • Docetaxel
    France Germany Ireland Spain

  • Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Infliximab
    • Mycophenolate Mofetil
    • Pembrolizumab
    Belgium Bulgaria France Germany Greece Ireland +4
1 2 3 … 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!